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Introduction
A study of Nordic families [1] has claimed ‘preliminary evi-
dence’ that a region on chromosome 13q might contain a
previously unrecognized tumour-suppressor gene, muta-
tions in which may be associated with an unknown but
probable high risk for breast cancer. This potentially excit-
ing finding was achieved using new molecular techniques
and ‘a strategy that assumed that somatic genetic
changes in cancer tissues may give insights to the nature
of the germline predisposing loci’.
Comparative genomic hybridization (CGH) was used to
study tumours from multicase breast cancer families.
Branching and phylogenetic tree models, and other evi-
dence suggested that loss of 13q was an early genetic
event in the development of breast cancers. All five
tumours from one particular family showed distinct 13q
deletions, which led to identification of a haplotype shared
by all five affected members that coincided with the region
of loss in the tumours identified by CGH. However, the
‘significance’ of the loss of homozygosity studies, in both
the statistical and common language meanings, is difficult
to assess, given that the role of chance was not evaluated.
A linkage study, in an independent set of multicase breast
cancer families in which BRAC1 and BRCA2 mutations
had been excluded, was then targeted on the region of
interest in their search for a novel breast cancer predispo-
sition locus that they termed BRCAX [1]. They consid-
ered their lod score results promising, although there was
no evidence of linkage in an interval that was only
0.5–2.1cM from the position of their BRCAX. Those
investigators were also confident that they could exclude
the role of BRCA2, which is not far (recombination frac-
tion 0.25) from where their putative locus lies, even
though they did not study extensively markers on both
sides of BRCA2. Is there really a BRCAX other than
BRCA2 on this chromosome?
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Abstract
A new gene associated with a high risk of breast cancer, termed BRCAX, may exist on chromosome
13q. Tumours from multicase Nordic breast cancer families, in which mutations in BRCA1 and
BRCA2 had been excluded, were analyzed using comparative genomic hybridization in order to
identify a region of interest, which was apparently confirmed and refined using linkage analysis on an
independent sample. The present commentary discusses this work. It also asks why there should exist
genetic variants associated with susceptibility to breast cancer other than mutations in BRCA1 and
BRCA2, and what might be their modes of inheritance, allele frequencies and risks. Replication studies
will be needed to clarify whether there really is a tumour suppressor gene other than BRCA2 on
chromosome 13q.
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What evidence is there that there are more
breast cancer genes?
Why would one think there are more genes associated
with a high risk for breast cancer other than BRCA1 and
BRCA2? The argument proposed in the first line of the
abstract of the report by Kainu et al [1] that such genes
must exist because there are so-called ‘familial breast
cancer families’ in which a BRCA1 or BRCA2 mutation
has not been detected is unconvincing. A nontrivial pro-
portion of the multicase breast cancer families studied by
Kainu et al will occur by chance alone, as demonstrated
by simulation studies [2] that addressed the observation
from population-based studies that the majority of heredi-
tary early-onset breast cancer is sporadic. For example,
even if the genetic risk of breast cancer (penetrance) is
80% to age 70 years (equivalent to a 20-fold increase in
the risk) and is carried by 1 in every 200 women, then
approximately 30% of families with three or more cases
of breast cancer spread over three generations will not be
due to that genetic risk. Use of the expression ‘familial
disease’ without precise definition, especially when used
as by these authors to refer to ‘hereditary disease’,
should be discouraged. Awful family histories can occur
through bad luck.
It is well known that having a blood relative who has had
breast cancer increases a woman’s risk for the disease.
This increased risk is modest, in terms of the individual,
being on average approximately twofold and higher if the
relative was diagnosed at a young age [3]. It has been
estimated that just 16% of this familial aggregation of
breast cancer in the UK diagnosed before age 55 years
could be attributed to mutations in BRCA1 and BRCA2
[4]. What explains the rest?
What about nongenetic causes of familial
clustering of breast cancer?
Familial aggregation does not imply a genetic aetiology;
consider infectious diseases such as the common cold,
for which clustering of disease within families can occur
for nongenetic reasons [5]. It is generally considered that
breast cancer is a hormonal disease, as evidenced by the
well-established risk factors identified from questionnaire
epidemiology (such as age at menarche, age at
menopause, parity, number of live births, and even a small
effect of oral contraceptive use), and from the change in
shape of the incidence curve around menopause. Further-
more, these classic risk factors are themselves ‘familial’, in
that sisters, mothers and daughters are moderately or
weakly correlated (ie r < 0.5).
How much of the familial aggregation of breast cancer is
due to the familial correlations in these risk factors? The
answer is, on face value, not very much. For example,
modelling has shown that five such independent risk
factors, each correlated (r=0.4) in first-degree relatives
and each associated with a doubling of risk across the
interquartile range, would result in an increased risk of
disease in relatives of just 1.05-fold [6]. However, it is
important to realize that the effect of these familial factors
could be substantially greater, given they are imprecisely
measured surrogates for the real underlying hormonal
determinants of breast cancer. Measurement error will
attenuate the estimates of both risk and familial correlation
[6]. On the other hand, the reasons why these risk factors
aggregate in families could at least partly be due to
genetic factors that influence their variation – it is not easy
to untangle nature and nurture.
A large proportion of familial aggregation of breast cancer
therefore remains unexplained. This is important; even a
modest twofold increased risk for disease cannot occur
unless there are underlying familial risk factors that, when
combined, are an order of magnitude stronger, giving an
interquartile risk ratio of 20–100 or more [7–9]. Uncover-
ing all of the sources of familial aggregation of breast
cancer will be a major step in understanding the causes of
the disease itself.
What about candidate genes?
The ATM locus that is implicated in the rare recessively
inherited disease ataxia-telangiectasia (A-T) has attracted
attention following the report of a threefold increased risk
in heterozygotes from linkage analyses in families contain-
ing A-T sufferers [9]. Several studies have since screened
A-T cases for protein-truncating and other mutations in the
gene (eg [10]) without finding supporting evidence.
However, only large, well-conducted population-based
studies have the statistical power and credibility to resolve
the issue, and those of even several hundred cases and
control individuals have little chance of detecting such
rare, modest risks [11]. Interest is now shifting to mis-
sense mutations [12] – clearly the jury is still out.
Common polymorphisms in other ‘candidate’ genes,
chosen for their presumed role in aetiological pathways,
have been examined without much success to date [13].
Based on epidemiological evidence, genes that are
involved in the metabolism of oestrogen would seem a
logical place to start. Initially there was evidence that a
T to C variant in the CYP17 gene (allele frequency about
0.4) played a role in serum oestrogen and progesterone
levels [14], and was associated with an increased risk of
advanced disease [15]. Subsequent case–control and
cohort studies [13] failed to support this as a genetic risk
factor. Tantalizing new evidence that women with two
copies of this allele may have a twofold to fourfold
increased risk of early-onset disease [16,17] demands
further study.
A common polymorphism in BRCA2 with an allele fre-
quency of about 0.25 may be associated with a 1.4- toBreast Cancer Research    Vol 3 No 3 Hopper
1.5-fold recessively inherited risk of the disease [18]
(Spurdle AB, et al, unpublished data). The roles of such
common polymorphisms are worthy of study because, in
terms of attributable risk and explaining familial aggrega-
tion on a population basis, they could be more important
than the rare high-penetrance mutations in genes such as
BRCA1 and BRCA2, or even BRCAX. For example, a
twofold risk carried by 20% of the population explains 20
out of 120 (17%) cases, whereas a 20-fold risk carried by
0.5% explains just 9.5 out of 109.5 (9%) cases.
What can we learn from segregation and
mutation analyses?
Segregation analyses attempt to estimate from family data
the characteristics (in terms of mode of inheritance, allele
frequency and risk of disease in carriers) of unmeasured
genetic variants that have a major impact on risk of
disease. Two recent analyses of population-based fami-
lies, in which extensive mutation testing for both BRCA1
and BRCA2 had been carried out, have been reported
[19,20]. By either removing the families in which mutations
are known to be segregating, or by modelling the effects
on risk of those identified mutations, these analyses
suggest that there may be genes other than BRCA1 and
BRCA2 that are involved with a dominantly inherited risk,
that there may be genetic loci that are involved with a
recessively inherited risk, and that there may also be a
‘polygenic’ background of many genes with small effects.
Extensive mutation and linkage analysis in multicase fami-
lies [21] has also provided evidence to suggest there may
be other ‘high risk’ susceptibility genes.
What is the way forward?
There would appear to be considerable evidence to
support projects aimed at identifying genes, other than
BRCA1 and BRCA2, that are involved in susceptibility to
breast cancer. What is evident is that these genes may
contain ‘high-risk’ or ‘moderate-risk’ alleles (and even both
within the same locus), and that the risk may be domi-
nantly or recessively inherited. Does the approach of the
recent report [1] represent the way forward, combining
thorough molecular work using tissue material and CGH
to help focus gene hunting, and independent verification
within the one study? Certainly others are following this
lead, using fresh tumour tissue to try to identify groups of
genes on the basis of their similarity in expression [22].
This may be the key to overcoming the difficulties in gene
discovery due to the genetic heterogeneity of susceptibil-
ity to individual cancers.
Conclusion
There is every possibility that are more 'breast cancer
genes', but whether these include ATM, CYP17, other
estrogen metabolism genes and/or the putative BRCAX
locus claimed by the Nordic researchers, is at present
unresolved.
The bottom line is whether others find supporting evi-
dence; as Kainu et al [1] themselves state, ‘studies to eval-
uate the significance of this candidate locus in other
populations will be critically important’. The answer of
course lies with replication.
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